Analysts Set COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Price Target at $16.25

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $16.25.

A number of brokerages have recently commented on CMPS. BTIG Research lifted their price target on shares of COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Monday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a report on Wednesday, January 21st. Morgan Stanley boosted their target price on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada increased their price target on COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, January 23rd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CMPS. Simplify Asset Management Inc. purchased a new position in shares of COMPASS Pathways during the 3rd quarter worth $1,662,000. Bridger Management LLC purchased a new stake in shares of COMPASS Pathways in the 2nd quarter worth $412,000. Schroder Investment Management Group bought a new position in COMPASS Pathways in the 2nd quarter worth $1,525,000. Stableford Capital II LLC bought a new position in COMPASS Pathways in the 2nd quarter worth $459,000. Finally, Hsbc Holdings PLC purchased a new position in COMPASS Pathways during the second quarter valued at $3,011,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Down 4.0%

CMPS stock opened at $6.71 on Friday. The stock has a market capitalization of $644.29 million, a P/E ratio of -2.47 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $8.20. The business has a fifty day moving average price of $6.51 and a 200-day moving average price of $5.66.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02. Equities analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.